The approval of TEPOXX in Japan marks another significant milestone in our mission to expand access to this critical ...

As we look ahead to the new year, your support makes all the difference. Make a donation today to help us continue bringing science to life for millions of readers.

On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment TEPOXX (tecovirimat 200 mg capsules) for smallpox, mpox, cowpox ...

Symptoms of monkeypox can also be compared with smallpox — a related virus that was declared eradicated in 1980. Like smallpox, monkeypox causes pus-filled boils. But monkeypox is generally ...

Accordingly, the oral treatment will also be indicated in Japan for adults and children weighing at least 13 kg to treat any complications linked to smallpox vaccination. The New York-based pharma ...

Chimerix in 2022 sold its smallpox treatment, Tembexa, to Emergent BioSolutions (NYSE: EBS) of Maryland for an upfront payment of $238 million — with the potential to earn more in milestones and ...

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpox Japan Biotechno Pharma Co., Ltd. engaged as exclusive ...

SIGA Technologies has gained Japanese regulatory approval for TEPOXX (tecovirimat) 200mg capsules, known as TPOXX in the US, for the treatment of smallpox, mpox and cowpox, and complications ...